Diffuse Large B-cell Lymphoma Responds to Tafasitamab plus Lenalidomide

Article navigation

Research Watch| August 03 2020

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2020

American Association for Cancer Research.

Cancer Discov (2020) 10 (8): 1091.

Abstract

Patients with relapsed or refractory diffuse large B-cell lymphoma responded to a novel combination.

2020

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.